These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35099785)

  • 1. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
    Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk Management Plans: reassessment of safety concerns based on Good Pharmacovigilance Practices Module V (Revision 2)-a company experience.
    Esslinger S; Quinn L; Sampat S; Otero-Lobato M; Noël W; Geldhof A; Herijgers N; Reeder SJ
    J Pharm Health Care Sci; 2022 May; 8(1):14. PubMed ID: 35509028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk minimization activities of centrally authorized products in the EU: a descriptive study.
    Zomerdijk IM; Sayed-Tabatabaei FA; Trifirò G; Blackburn SC; Sturkenboom MC; Straus SM
    Drug Saf; 2012 Apr; 35(4):299-314. PubMed ID: 22339506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP.
    Marshall R; Atuah KN; Tekumalla SH
    Pharmaceut Med; 2020 Feb; 34(1):1-5. PubMed ID: 32048215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Management Plans: are they a tool for improving drug safety?
    Frau S; Font Pous M; Luppino MR; Conforti A
    Eur J Clin Pharmacol; 2010 Aug; 66(8):785-90. PubMed ID: 20577875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance.
    Sardella M; Belcher G; Lungu C; Ignoni T; Camisa M; Stenver DI; Porcelli P; D'Antuono M; Castiglione NG; Adams A; Furlan G; Grisoni I; Hall S; Boga L; Mancini V; Ciuca M; Chonzi D; Edwards B; Mangoni AA; Tuccori M; Prokofyeva E; De Gregorio F; Bertazzoli Grabinski Broglio M; van Leeuwen B; Kruger P; Rausch C; Le Louet H
    Ther Adv Drug Saf; 2021; 12():20420986211038436. PubMed ID: 34394910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
    Hirota S; Yamaguchi T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
    Lane S; Lynn E; Shakir S
    BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union.
    Hoeve CE; Francisca RDC; Zomerdijk I; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2020 Jan; 43(1):45-55. PubMed ID: 31617081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk management plans as a tool for proactive pharmacovigilance: a cohort study of newly approved drugs in Europe.
    Vermeer NS; Duijnhoven RG; Straus SM; Mantel-Teeuwisse AK; Arlett PR; Egberts AC; Leufkens HG; De Bruin ML
    Clin Pharmacol Ther; 2014 Dec; 96(6):723-31. PubMed ID: 25222619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.
    Banerjee AK; Zomerdijk IM; Wooder S; Ingate S; Mayall SJ
    Drug Saf; 2014 Jan; 37(1):33-42. PubMed ID: 24357107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to risk management plans in the Singapore context.
    Ho CSC; Tan LLB; Chan CL
    Singapore Med J; 2019 Sep; 60(9):483-486. PubMed ID: 31570951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.